UBS initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Nurix has a “differentiated” BTK degrader that is “poised to disrupt” the $9B BTK market, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright
- Nurix Therapeutics Appoints Anil Kapur to Board
- Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Nurix Therapeutics Braces for Stricter Disclosure Rules as Market Value Grows